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1. Introduction 
Protein aggregation is a very fascinating matter due to its implication in many human 
neurodegenerative diseases and its relevance in food and pharmaceutical industries. In 
some cases, the aggregation of protein is a natural phenomenon occurring in living 
organisms. For example, in the reaction leading from the globular (G) monomeric actin to its 
polymeric fibrillar (F) structure (Morris et al., 2009): 
n (G-Actin)  (F-Actin)n 
or the case of polymerization of tropocollagen to obtain collagen fibrils, a process leading, in 
the case of  type I Collagen, to the formation of long fibrils having a wave pattern (Yadavalli 
et al., 2010).  
In general, a non-physiological aggregation, that is an aggregation process not naturally 
occurring, starts from “activated” molecules having secondary and/or tertiary structures 
different from those corresponding to the “native state” (Manno et al., 2006, 2010; Morris et 
al., 2009).  Increasing evidence suggests that the non-physiological aggregation of proteins 
such beta-amyloid, alpha-synuclein, huntingtin and ataxin, superoxide-dismutase 1 (SOD1), 
Tau and Amylin, is responsible for the onset of many neurodegenerative pathologies such 
as Alzheimer’s, Parkinson’s and Huntington’s diseases, Amyotrophic Lateral Sclerosis, 
Frontotemporal Lobar Degeneration (Figure 1) and Type 2 Diabetes (or diabetes mellitus), 
respectively (Chiti & Dobson, 2006). 
The question of what triggers the transformation of a biologically active protein into a 
“pathogenic agent” with high self-assembly propensity is still unanswered. Some of the 
proposed explainations include:  
i. the propensity of some proteins to assume a pathological conformation which increases 
with aging (Uversky, 2007; Saraiva, 2001); 
ii. the persistently high cellular or plasma concentrations (Singleton et al., 2003; Farrer et 
al., 2004); 
iii. an amino acid mutation or a genetic expansion of DNA sequences encoding proteins, as 
in the case of Huntington disease (Cummings & Zoghbi, 2000); 
iv. an abnormal post-traslational modification of the protein responsible for the disease 
(Goedert et al., 1993); 
www.intechopen.com
 
Topics in the Prevention, Treatment and Complications of Type 2 Diabetes 
 
30
v. the proteolitic cleavage of the precursor protein, as in the case of Abeta-peptide; 
vi. the influence of environmental factors. 
 
 
Fig. 1. Protein misfolding and aggregation as the common molecular pathogenesis of 
neurodegenerative diseases. Some genetic mutations responsible of neurodegenerative diseases 
render the causative proteins prone to misfold and to form beta-sheet-rich oligomers and 
amyloid fibrillar aggregates, resulting in their accumulation in the affected neurons and 
eventually leading to degeneration in the brain. This mechanism is retained common to a 
broad variety of neurodegenerative diseases, such as Alzheimer’s, Parkinson’s and 
Huntington disease, Amyothophic Lateral Sclerosis  and Frontotemporal Lobar 
degeneration. 
Type 2 diabetes (T2D) is classified as a metabolism disorder and it is often associated with 
microvascular and macrovascular complications, including retinopathy, nephropathy, 
neuropathy and cardiovascular disease. A diabetes affected person has an elevated quantity 
of glucose in the blood (hyperglycemia) that is caused by the inability of the body either to 
produce any insulin or enough insulin, or by the inability of the cells to respond properly to 
the insulin producted in the pancreas. This excess blood glucose eventually passes out of the 
body in the urine. So, even though the blood has plenty of glucose, the cells are incapable of 
getting it for their essential energy and growth requirements. There are three main types of 
diabetes: Type 1 diabetes (T1D) (referred to as insulin-dependent diabetes and juvenile 
diabetes), results from the body's failure to produce insulin, and presently requires the 
person to inject insulin. Type 2 diabetes (referred to as non-insulin-dependent diabetes 
mellitus, and adult-onset diabetes.) is associated with a reduced ability of insulin to stimulate 
glucose utilization (insulin resistance) and sometimes it is combined with an absolute 
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insulin deficiency. The third type, gestational diabetes, is when pregnant women, who have 
never had diabetes before, have a high blood glucose level during pregnancy and it may 
precede development of T2D. Ninety percent of diabetes patients have T2D, which usually 
has its onset in adulthood. Diabetes is increasing and the World Health Organization 
estimates that there will be a doubling of cases by 2025, largely as a result of lack of physical 
activity and poor dietary habits, both of which are risk factors for the disease. Obesity, 
hypertension, hyper-cholesterolemia and hyperlipidemia are all associated with T2D 
(MedScape). 
 Alzheimer’s disease (AD) is the most common form of dementia in the elderly. It is 
characterized by neuronal cell loss and increasing accumulation of neurofibrillary tangles 
(NTF) in neurons and amyloid fibers in neuritic plaques and in the walls of blood vessels 
(Wisniewski et al., 1997). Amyloid beta-peptides of varying length (39–43 residues) are 
produced by cleavage of a transmembrane protein, the amyloid beta-protein precursor 
(APP) (Wilquet & De Strooper, 2004). The 42 residue beta-peptide (Abeta-42) is the 
predominant form found in plaques and under physiological condition the ratio between 
Abeta42 and Abeta40 is about 1:10 (Iwatsubo et al., 1994). Abeta42 has a much greater 
neurotoxity than Abeta40 and its aggregation kinetics is faster than other beta-petides 
(Davis & Van Nostrand, 1996). The proteinaceous material is organized in structured linear 
aggregates (amyloid fibrils). A recent and now convincing belief is that small diffusible 
oligomers of Abeta-42, called ADDLs, are the determining pathogenic species causing 
synaptic dysfunction and eventually neuronal degeneration (Lambert et al., 1998; Picone et 
al., 2009) 
AD accounts for 50–70% of all dementia cases and is characterized by cognitive deficits. This 
incurable, degenerative, and terminal disease was first described by the German psychiatrist 
and neuropathologist Alois Alzheimer in 1906. Several factors have been considered 
relevant for the AD pathogenesis and among these the most important is age. During life 
small variations occurring in cellular metabolism and structure can modify the functional 
state of susceptible neurons, leading to dramatic or even lethal changes. Thus, while the the 
monomeric Abeta is not neurotoxic, for not yet known reasons it starts to form 
supramolecular aggregates accumulating in the AD brain. 
Familial AD is a rare form of dementia and is caused by autosomal dominant mutations in 
one or more of the genes encoding the amyloid precursor protein (APP), presenilin 1 or 
presenilin 2 (the latter two proteins form the catalytic core of γ-secretase) (Gotz et al., 2004). 
By contrast, late-onset AD might be caused by environmental and/or life style factors 
(Rocchi et al., 2003). Interestingly, late-onset AD is characterized not only by the 
neuropathological markers mentioned above, but also by vascular lesions, and 
hyperglycemia, hyperinsulinemia, insulin resistance, glucose intolerance, adiposity, 
atherosclerosis and hypertension (Haan, 2006). 
Diabetes and AD are considered age-related diseases and are both increasing. In the USA, 
diabetes and AD affect ≈ 23.6 and ≈ 5.3 million people, respectively, and these numbers are 
projected to rise considerably. The Centers for Disease Control and Prevention predict that 
more than 29 million people in the US will be affected by diabetes by 2050, while the 
Alzheimer’s association forecasts that by this date, 11–16 million Americans will have AD 
(Han & Li, 2010). Numerous studies report that patients with diabetes have an increased 
risk of developing AD compared with healthy individuals (Arvanitakis et al., 2004; 
Neumann et al., 2008; Roriz-Filho et al. 2009). In fact, some studies revealed that 80% of 
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patients with AD exhibited either impairments in glucose tolerance or frank diabetes 
(Schrijvers et al., 2010). In particular, similarities between T2D and AD include: aging-
related processes, degeneration, high cholesterol levels, peripheral and CNS insulin 
resistance, dysfunctional IR and IR-mediated signaling pathways, decreased glucose 
transport and metabolism, despite the higher non-metabolized glucose levels in cerebral 
blood (Hoyer, 1998; Salkovic-Petrisic & Hoyer, 2007; Schulingkamp et al., 2000). The 
inbalance between low and high glucose levels in T2D patients may be responsible for brain 
vascular damage and neurodegeneration thus facilitating the AD onset.  
2. Alzheimer’s disease and type 2 diabetes: Two amyloidogenic pathologies 
AD and T2D are two pathologies characterized by the presence of large insoluble aggregates 
having an amyloidogenic fibrillar conformation, amylin in T2D pancreatic islets and Abeta 
and the microtubule protein Tau in the brain of AD patients. In particular, amylin 
aggregation is associated with pancreatic b-cell loss, whereas Abeta and Tau aggregation is 
associated with neuronal cell loss and synaptic dysfunction (Lupi & Del Prato, 2008; 
Schroeder & Koo, 2005; Resende et al., 2008a). The formation of amyloid aggregate occurs 
both in the intra- and extra-cellular environments; further the proteinaceous aggregates are 
strictly bound with membranes and calcified. Despite their common secondary structure 
conformation, it is well accepted that a correlation does not exit between amino acid 
sequence and tendency to amyloid structure formation; thus it is assumed that amyloid 
formation is a generic properties of all polypeptides (Chiti & Dobson, 2006).   
In particular, amyloid fibers share the following features (Xu, 2007): 
 all have a rope-like appearance; 
 all show a dominant beta-sheet structure; 
 their formation can be enhanced either by the stirring or the presence of seeds; 
 all aggregate starts from spherical oligomers that in turn self-assemble linearly; 
 all can incorporate a special kind of dye molecules such as Congo Red or Thioflavin T. 
 On a molecular lengthscale, Abeta can form aggregates of different shape originated in 
vitro under different conditions. These structures include amyloid fibrils (Ban et al., 2004), 
small oligomers (Walsh et al., 1999), spherical amyloid oligomers (Westlind-Danielsson & 
Arnerup, 2001) and annular pore-forming structures (Lashuel et al., 2002), amyloid 
protofibrils (Harper et al., 1997), beaded chain protofibrils (Huang et al., 2000) and 
spherocylindrical micelles (Lomakin et al., 1996; Yong et al., 2002).  
X-ray fiber diffraction showed that amyloid fibrils contain beta-sheet structure lying 
orthogonally to the major fibril axis (Serpell, 2000). In the early 2000s, Tycko’s group 
(Antzutkin et al., 2000; Balbach et al., 2002) obtained, for the first time, evidence of an 
extended parallel beta-sheet organization for the Abeta40 fibrils using solid-state NMR. 
They showed that the methyl carbons of Ala-21 and Ala-30 must be placed in groups of at 
least four with internuclear distances of less than 5.5 Å. Although beta-sheets are the main 
constituent of the amyloid fibrils they are not the only structure present in the fibrils. Liquid 
state NMR, FTIR and CD measurements in Abeta40 have demonstrated the existence of a 
turn formed by the amino acids at position 26-29. Little information is known about the 
Abeta42 fibril structure and many mutant peptides have been synthetized to obtain an 
explanation about its secondary structure. The results have showed that the residues at 
positions 15–21 and 24–32 are involved in the beta-sheet formation and that the turn at 
positions 22 and 23 plays a crucial role in the aggregation of Abeta42. 
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The islet amyloid polypetide (IAPP), identified for the first time in 1987 (Westermark et al.) 
and also known as amylin, is secreted by the beta cells of the pancreatic islets of Langerhans, 
which also secrete the insulin. The occurrence of IAPP in the membranes of beta-cells and 
the presence of alterations in the membranes of the same cells (Lorenzo et al., 1994; Janson et 
al., 1999) suggest that this interaction is responsible for the cytotoxic effect of these 
formations. The primary sequence of the peptide is well conserved in organisms and, in 
particular human and mouse IAPPs differ by only six amino acids but the latter does not 
form fibrils neither in vitro nor in vivo. The development of IAPP deposits is deeply 
associated with T2D because more than 90% of T2D patients presents this type of amyloid 
formations as evidenced by autopsy and, further, the amount of aggregates appears to be 
correlated with the pathology seriousness. 
Human IAPP (hIAPP) consists of 37 amino acids with a S-S bridge between the Cys 2 and 
Cys 7. As in Abeta, IAPP is non-toxic in its monomeric form but it exhibits high toxicity 
levels when it aggregates into beta-rich amyloid structures. As in other amyloid peptides, 
the mechanism of fibrillation occurs through the formation of nuclei with a lag phase whose 
duration is concentration-dependent and proceeds by addition of monomers or oligomers to 
both fibril terminals. The secondary structure of hIAPP mainly consists of unstructured 
regions, with small alpha-helical and beta-sheet components (Goldsbury et al., 2000). 
Recently has been suggested that hIAPP oligomers in presence of membranes could exhibit 
an alpha-helical structure (Knight et al., 2006). 
The three dimensional structure of hIAPP has been extensively studied with different 
techniques and the results show that, similarly to other amyloid proteins, the amylin mature 
amyloid fibrils show a relevant amount of beta-structure (McLean, 1992; Goldsbury, 2000). 
Studies on the mechanism of hIAPP fibrillation indicate that during the process, hIAPP 
undergoes a conformational change from an unstructured peptide to beta-sheets and alpha-
helical structures (Goldsbury, 2000). 
The IAPP decapeptide sequence between residues 20-29 seems to play an important role in 
the fibrillization process (Westermark et al., 1990) even if it does not appear to be the only 
region involved in fibril formation. In fact, recent studies have evidenced the importance of 
the residues in position 13-18 in the interaction leading to the formation of fibrils (Gilead & 
Gazit, 2008). Also the aromatic-aromatic interactions between residues 15, 23 and 37 seem to 
be important in amyloid formation althought not essential for fiber formation as evidenced 
using IAPP with a triple mutation (Marek et al., 2007).  
3. The effect of oxidative stress 
The brain has a high energy demand and, although it represents only 2% of body weight, it 
accounts for 20% of total body oxygen consumption. This energy requirement is largely 
driven by neuronal request of energy to maintain the ion gradients across the plasma 
membrane, which are critical for the generation of action potentials. This intense energy 
requirement is continuous; even brief periods of oxygen or glucose deprivation result in 
neuronal death. Diabetes mellitus leads to functional and structural changes in the brain, 
which appear to be most pronounced in the elderly. Furthermore, increased age is 
associated with insulin resistance. Increasing data support the idea that mitochondrial 
function declines with aging and in age-related diseases such as diabetes and AD. 
Normal glucose metabolism is required for the performance of cognitive functions, and 
impairments in glucose metabolism might contribute to cognitive dysfunction. Imaging 
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studies have revealed that patients with AD and individuals at risk of developing this 
disease typically have reductions in glucose metabolism in temporal and parietal brain 
regions and hippocampus (Garrido et al., 2002). Moreover, compared to healthy individuals, 
patients with AD often have increased plasma insulin levels and/or a decreased 
cerebrospinal fluid (CsF)-to-plasma insulin ratio. These findings indicates that glucose 
metabolism and insulin signaling are important in normal brain function. The negative 
effect of impaired glucose metabolism on cognitive functioning can be caused by an increase 
in oxidative stress that is associated with mitochondrial dysfunction.  
Mitochondria are essential subcellular organelles for generating the energy that fuels normal 
cellular functioning. At the same time, the mitochondria have a strategic task because, 
depending on environmental factors, they can decide whether to continue the healthy life of 
the cell or to terminate it by apoptosis activation.  Mitochondria are essential for neuronal 
function because the limited glycolytic capacity of these cells makes them highly dependent 
on aerobic oxidative phosphorylation for their energetic needs. However, oxidative 
phosphorylation is a major source of endogenous free radicals. A variety of reactive oxygen 
species (ROS) and reactive nitrogen species (RNS) are produced in vivo through both 
enzymatic and non-enzymatic routes. ROS include hydrogen peroxide, hydroxyl radical, 
superoxide ion and singlet oxygen, products of normal cellular respiration. The hydroxyl 
radical is a highly reactive species and has a relatively short life time. It is abundantly 
produced in the mitochondria during respiration cycles and reacts with the proteins, lipids, 
and nucleic acids during their production. Peroxynitrous acid is one of the major RNS found 
intracellularly and it is involved in the rapid nitration of aromatic residues of proteins, such 
as tyrosine, to give 3-nitrotyrosine, which may alter the protein structure. Further it is also a 
marker of oxidative stress (Smith et al., 1997). Under normal conditions, antioxidant 
defenses can counteract oxidative stress damage. In the absence of an appropriate 
compensatory response from the endogenous antioxidant network, the system becomes 
redox imbalanced, leading to the activation of a stress-sensitive intracellular signaling 
pathway and, in extreme conditions, to apoptosis. Increased oxidative damage and impaired 
antioxidant defenses are prominent both in the onset of AD and diabetes (Smith et al., 1996; 
Evans et al. 2002). Abnormal glucose metabolism can also increase the production of free 
radicals such as reactive oxygen species (ROS) and reactive nitrogen species (RNS). This 
overproduction of free radicals can exhaust the antioxidant capacity of the cell and lead to a 
condition known as oxidative stress, which is a hallmark of both T1D and T2D and a 
contributing factor to diabetic neuropathy (Russell et al., 2008; Vincent et al., 2004). 
Oxidative stress is not only associated with diabetes and its complications, but has been 
linked to insulin resistance, the subnormal response to a given amount of insulin (West, 
2000). 
ROS-induced and RNS-induced protein modifications and/or lipid peroxidations result in 
cell damage that can lead to cell death, and they are increased in patients with diabetes or 
AD compared with healthy controls (Pratico et al., 2004). Brain and cerebrospinal fluid (CSF) 
levels of lipid peroxidation biomarkers, including malondialdehyde and 4-hydroxynonenal 
(two highly toxic products generated in part by lipid oxidation and ROS),  are both higher in 
individuals with AD and diabetes mellitus than in healthy people (Reddy et al., 2009; Slatter 
et al., 2000). Furthermore, levels of oxidized proteins are increased in the frontal and parietal 
lobes and in the hippocampus of patients with mild cognitive impairment compared with 
healthy controls, indicating that oxidative damage might occur early in the development of 
AD (Butterfield et al., 2007). ROS, as mentioned earlier, are also involved in the damage of 
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DNA. Minor modifications of the nucleic acid bases are repaired through base excision 
repair involving DNA glycosylase and AP endonuclease, which are located in nuclei and 
mitochondria. The progression of AD is associated with the diminished expression of these 
DNA repair enzymes (Nakabeppu et al., 2004). The accumulation of the oxidatively 
damaged nucleic acids and proteins likely exceeds the limit of cellular repair and 
detoxification mechanisms and leads to the onset or progression of diabetic and 
neurological pathologies. In general, accumulation of oxidatively damaged proteins, lipids, 
and nucleic acids correlates with the onset of age-related diseases, especially in diabetes and 
AD (Stadtman, 2001), indicative of a common pathological mechanism. 
Oxidative stress and lipid peroxidation seem to be able to induce Abeta accumulation: 
studies in a mouse model of AD have demonstrated that brain lipid peroxidation increases 
before that Abeta levels increase (Pratico et al., 2001) and that the onset of Abeta deposition 
is associated with an increase in the level of RNS (Apelt et al., 2004). Further evidence 
supporting this hypothesis has been obtained from studies of a mouse model of AD in 
which mutations in the genes encoding APP and presenilin 1 cause an increase in Abeta42 
production. In these animals, lipid and protein peroxidation is evident at the disease onset 
(Matsuoka et al., 2001).  In a triple-transgenic animal model of AD, in which mice develop 
Abeta plaques, tangles and cognitive defects, a decrease in antioxidant capacity and an 
increase in lipid peroxidation were noted before the development of AD pathology 
(Resende et al., 2008).  Oxidative stress seems to affect APP either directly, by increasing 
APP levels, or indirectly, by modulating APP processing, and both mechanisms could 
increase levels of Abeta. Studies in transgenic mice and postmortem brain tissue from 
patients with AD suggest also that an increase in Abeta production leads to a rise in the 
production of ROS and that oxidative stress occurs early in the development of the disease.  
4. The mitochondrial dysfunction 
Several studies are consistent with the view that diabetes-related mitochondrial dysfunction 
is exacerbated by aging and/or by the presence of neurotoxic agents, such as Abeta. This 
suggests that diabetes and aging are risk factors for the neurodegeneration induced by this 
peptide. Mitochondrial dysfunction could be one of the common underlying mechanisms 
explaining the association between diabetes and AD. Mitochondrial dysfunction and the 
resulting energy deficit trigger the onset of neuronal degeneration and death. Mitochondria 
serve also as high capacity Ca2+ sink, which allows them to follow the changes in cytosolic 
Ca2+ loads and helps in maintaining cellular Ca2+ homeostasis, required for normal neuronal 
function (Rizzuto et al., 2000). Conversely, excessive Ca2+ uptake inside mitochondria has 
been shown to increase ROS production, inhibit ATP synthesis, release cytochrome C, and 
induce mitochondrial permeability transition (Brustovetsky et al., 2002). The mitochondrial 
permeability transition (MPT) is defined as the sudden increase of inner mitochondrial 
membrane permeability to solutes of molecular mass lower than 1500 Da (Bernardi et al., 
1994). Strong evidence now exists that the MPT is due to the opening of a nonselective 
megachannel (estimated to be 2–3 nm in diameter). Because the chemiosmotic theory is 
based on the impermeability of the inner mitocondrion membrane to solutes that are not 
specifically transported, MPT would collapse the mitochondrial membrane potential (ΔΨm) 
and uncouple the electron transport system from the production of ATP. Additionally, MPT 
results in mitochondrial swelling and can lead to the release of proapoptotic proteins. 
Importantly, Ca2+, Pi, oxidative stress, and low inner membrane potential promote the onset 
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of MPT, whereas cyclosporin A, Mg2+, ADP, and the existence of a high membrane potential 
oppose the onset (Bernardi et al., 1994). 
Increasing data support the idea that mitochondrial function declines with aging and in age-
related diseases, such as diabetes and AD (Calabrese et al., 2001). Some data show the 
existence of an age-related impairment of the respiratory chain and an uncoupling of 
oxidative phosphorylation in brain mitochondria isolated from Goto-Kakizaki (GK) rats, as 
model of T2D (Moreira et al., 2003). Furthermore, aging exacerbates the decrease in the 
energetic levels promoted by diabetes. The maintenance of oxidative phosphorylation 
capacity is extremely important in the brain since a large amount of the energy required for 
the normal functioning of neurons is provided by mitochondria. Moreover, the CNS 
requires a large amount of ATP for the transmission of impulses along the neural pathway, 
thus indicating that mitochondrial function impairment can result in neurodegeneration and 
loss in neuronal metabolic control (Calabrese et al., 2001). 
5. Advanced glycation end products (AGE) 
Abnormal glucose metabolism and oxidative stress contribute to the formation of advanced 
glycation end products (AGE). This process occurs through the Maillard reaction or “non-
enzymatic browning”, a complex series of reactions between reducing carbohydrates with 
lysine side chains and N-terminal amino groups of proteins. This process initially leads to 
rather labile Schiff bases which as a rule rearrange to the more stable Amadori products. The 
Amadori compounds are slowly degraded, in complex reaction pathways via dicarbonyl 
intermediates, to a plethora of compounds (Ledl & Schleicher, 1990) designated summarily 
as “advanced glycation end products” (AGEs); this overall reaction sequence proceeds both 
in vitro and in vivo. In long-lived tissue proteins, these chemical modifications accumulate 
with age and may contribute to pathophysiologies associated with aging and long-term 
complications of diabetes and atherosclerosis (Lederer & Klalber, 2000). 
Practically, AGEs comprise a heterogeneous group of molecules formed by irreversible, 
non-enzymatic reactions between sugars and the free amino groups of proteins, lipids and 
nucleic acids. Auto-oxidation of glucose leads to the formation of oxygen radicals, which are 
intermediates in the AGE pathway and the predominant source of endogenous AGEs. AGEs 
may exist as protein cross-links or as modification of the side chains of a single protein, and 
significantly alter protein conformations leading to protein inactivation. Numerous AGEs 
have been isolated and characterized by spectroscopic analysis after cleavage from the 
protein backbones. AGEs involving protein cross-links include: pentosidine, a dimer of 
arginine and lysine; methylglyoxal-lysine dimer (MOLD), a dimer of two lysine residues; 
and methylglyoxal-derived imidazolium cross-link (MODIC) and glyoxal-derived 
imidazolium cross-link (GODIC), dimers of arginine and lysine residues. Examples of AGEs 
resulting from the single protein modification are pyrraline and Nε -(carboxymethyl)lysine 
(CML), the lysine-residue modified products, and argpyrimidine, an arginine-residue 
modified protein. Although many other AGEs, including the hydroimidazolone adduct MG-
H1, have been characterized in diabetes, some of them have common occurrence in AD 
(Rabbani et al., 2008). 
The formation and accumulation of AGEs occur during normal aging; however, these 
processes are exacerbated in patients with diabetes and the binding of AGE to its receptor 
(receptor for AGEs or RAGE) induces a series of biological processes that cause further 
diabetic complications (Singh et al., 2001). AGE immunoreactivity is present in both Abeta 
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plaques and NFTs in patients with AD. Furthermore, hippocampal neurons from patients 
with this neurodegenerative disease contain Abeta-positive, AGE-positive and RAGE 
positive granules. (Sasaki et al., 2001). Whether the modifications of Abeta and tau by AGEs 
are a primary or secondary event in AD is a controversial topic. Nevertheless, AGEs are 
widely accepted to be active participants in the progression of AD, since AGE-induced 
glycation of Abeta and tau protein has been shown to cause the Abeta aggregation and the 
formation of NFTs, respectively (Ledesma et al., 1994). Moreover, diabetic mice with 
cognitive impairments exhibit increased RAGE expression in neurons and glia compared 
with wild-type control mice (Toth et al. 2006), and in one clinical study, AGE 
immunostaining was increased in postmortem brain slices from patients with AD and 
diabetes compared with non-diabetic patients with AD (Girones et al., 2004). 
The question of whether AGEs are the cause or consequence of the pathology is not clear, 
although there is likely a primary role of oxidative stress in both pathologies. However, it 
should be pointed out that glycoxidation and oxidative stress are mutually dependent and 
reinforce each other. Thus, while the sources of oxidative stress may widely differ in 
diabetes and AD, and while a number of AGEs accumulate in both conditions, other AGEs 
found in diabetes have yet to be characterized in AD. 
6. Antioxidant therapy in Alzheimer’s disease and diabetes 
Given the importance of mitochondria as the primary source of oxidative stress in AD and 
diabetes, the use of antioxidants may also be useful. However, the broad occurrence of both 
diseases, the non-regenerative nature of the CNS and the fact that AD diagnosis often does 
not occur until late in the disease progression, suggest that the ideal antioxidant should be 
used as a prophylactic treatment for the aged population. Oxidative stress is one of the 
earliest events in the neurological and pathological changes of AD, while the effects of 
oxidative stress are manifested in the slow accumulation of AGEs in diabetes. Thus, 
antioxidant therapy in combination with AGE inhibitor therapy may be effective approaches 
for AD and diabetes-related complications. Oxidative stress leads to  irreversible protein 
aggregation and consequent neuronal degeneration in AD (Liu et al., 2007). Advanced 
lipoxidation products, such as HNE, bind to phosphorylated tau protein to form paired 
helical filaments, accelerating the formation of neurofibrillary tangles. Oxidative stress also 
results in the covalent crosslinking of tau filaments to form large aggregates that are 
resistant to proteolytic cleavage. Larbig and coworkers reported a series of inhibitors for tau 
protein aggregation (Larbig et al., 2007). Remarkably, thiazolium-based compounds, which 
are also AGE inhibitors and potentially useful for diabetic therapy, are effective inhibitors of 
tau aggregation.  
Extensive studies of pharmacological interventions based on biological antioxidants have 
been carried out both for AD and diabetes (Lee et al., 2010; Maritim et al., 2002). Common 
antioxidants include the vitamins A, C, and E, glutathione, and the enzymes superoxide 
dismutase, catalase, glutathione peroxidase, and glutathione reductase. Other antioxidants 
include lipoic acid, mixed carotenoids, coenzyme Q10, several bioflavonoids, antioxidant 
minerals (copper, zinc, manganese, and selenium), and the cofactors (folic acid; vitamins B1, 
B2, B6 and B12). They work in synergy with each other and against different types of free 
radicals. Vitamin E suppresses the propagation of lipid peroxidation; vitamin C, with 
vitamin E, inhibits hydroperoxide formation; metal complexing agents, such as 
penicillamine, bind transition metals involved in some reactions in lipid peroxidation.  
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Vitamins A, C, and E are interesting antioxidant molecules because are diet-derived and 
directly detoxify free radicals. They also interact in recycling processes to generate reduced 
forms of the vitamins. Tocopherol is reconstituted when ascorbic acid recycles the tocopherol 
radical; dihydroascorbic acid, which is generated, is recycled by glutathione. Under some 
conditions, these vitamins also foster toxicity by producing pro-oxidants. Vitamin E, a 
component of the total peroxyl radical-trapping antioxidant system, reacts directly with 
peroxyl and superoxide radicals and singlet oxygen and protects membranes from lipid 
peroxidation (Weber et al., 1997). A deficiency of vitamin E is concurrent with increased 
peroxides and aldehydes in many tissues. There have been conflicting reports about vitamin E 
levels in diabetic animals and human subjects. Plasma and/or tissue levels of vitamin E are 
reported to be unaltered, increased, or even decreased by diabetes (Asayama et al., 1994).  
Some AGE inhibitors and AGE crosslink breakers have been utilized as potential therapies. 
Some attention to AGE inhibitors was focused on aminoguanidine, which blocks 
electrophilically activated 1,3-dicarbonyl compounds, the precursors of AGEs (Thomas et al. 
2005; Webster et al., 2005). This compound was not approved by the US Food and Drug 
Administration due to adverse side effects in diabetic patients during Phase III clinical trials, 
and the search to find alternatives continues. Pyridoxamine (vitamin B6, pyridorin) and 
thiamin pyrophosphate have been proposed as potential alternatives to aminoguanidine 
(Ahmed et al., 2007; Androver at al., 2008). Furthermore, these compounds are also good 
metal ion chelators and attenuate oxidative stress. N-acetylcysteine and lipoic acid act as 
inhibitors through attenuation of oxidative stress. While the AGE-inhibitory effect of these 
compounds is not clearly understood, a similar mechanism may operate in the case of 
AGEs. Carnosine, homocarnosine, and related compounds are potentially suitable as AGE 
inhibitors although further studies are needed to prove their efficacy in diabetes and AD 
(Reddy et al., 2005). Carnosine protects superoxide dismutase, catalase, and -crystallin 
from non-enzymatic glycation and protein crosslinking (Hipkiss, 2007). OPB-9195 inhibits 
AGE formation, especially pentosidine and N-(carboxymethyl)lysine (CML), apparently 
through carbonyl trapping and metal ion chelation (Wada et al., 2001). Thiazolium-based 
compounds such as alagebrium chloride (ALT-711) and N-phenyacyl-1,3-thiazolium 
bromide (PTB) are effective AGE crosslink breakers, and are potentially useful drugs for 
diabetes and AD (Susic, 2007). It should, however, be pointed out that the mechanisms of 
the action of the latter compounds are not clearly understood. In addition to their action as 
crosslink breakers of AGEs derived from 1,2-dicarbonyl compounds, they may also act as 
antioxidants through chelation of transition metal ions. The development of these drugs as 
therapeutics thus depends on the detailed understanding of their mechanisms of action. An 
alternative strategy involves removal of AGEs through the soluble receptors for AGEs 
(sRAGEs). Poor glycemic control in diabetes results in decreased concentrations of sRAGES, 
and upon insulin treatment, significant improvements in the levels of sRAGEs were 
observed, with concomitant decrease in AGEs (Devangelio et al., 2007). Treatment of 
diabetic patients with rosiglitazone, a 2,4-thiazolidine dione derivative, results in increase of 
plasma sRAGEs, comparable to controls (Tan et al., 2007). Significant amounts of plasma 
sRAGEs are also produced when angiotensin converting enzyme inhibitors (ACEi; e.g., 
perindopril) were used for the treatment of diabetes (Tan et al., 2006). However, the 
protective effect of sRAGEs has been questioned recently as their level are much higher in 
experimental animal models than those found in vivo, suggesting they may be only markers 
of inflammation (Humpert et al., 2007). Following the trend in using natural antioxidants, a 
recent paper has examined the effects of banana (Musa sp. var. elakki bale) flower and 
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pseudostem on hyperglycemia and AGEs in streptozotocin-induced diabetic rats. The 
results indicate that fructosamine and AGEs formed during diabetes were inhibited in 
treated groups when compared with the diabetic group (Bhaskar et al., 2011).  
However, the results of clinical trials of antioxidant therapy are not clear because of duration 
of treatment as well as recruitment of patients at different stages of the diseases. In spite of 
inconsistency in the conclusions of clinical trials on the beneficial effects of antioxidants on 
these pathologies, epidemiological studies indicate that antioxidants may reduce the risk of 
their insurgence. It is suggested that a combination of antioxidants might be of greater 
potential benefit, especially if these agents work in different cellular compartments or have 
complementary activity (e.g. Vitamins E, C, and ubiquinone). If oxidative stress plays as 
important a role in AD and diabetes pathologies as the literature suggests, regular intake of 
antioxidants may be beneficial much before any sign or symptoms of the disease are visible.  
7. Insulin resistance, Tau hyperphosphorylation and the amyloid cascade 
In addition to being a modulator of food intake and energy homoeostasis, insulin is also an 
important neurothrophic factor. It modulates brain activity, particularly for such high 
glucose demanding functions such as memory. As mentioned above, T2D is associated with 
cognitive impairment. This form of diabetes is characterized by insulin resistance, 
hyperinsulinemia and impaired insulin signaling. Insulin resistance is the common link of 
the components of the much invoked metabolic syndrome (a cluster of high adiposity, 
abnormal glucose level, dyslipidemia, hypertension and high inflammation) and it is known 
to cause common diseases such as stroke, heart disease, and cancer. Given the aging of the 
population and the epidemic of elevated insulin resistance, evidenced by the rise in elevated 
adiposity, prediabetes, and diabetes, it is alarming that insulin resistance could contribute to 
AD. Many epidemiologic studies have found an association of elevated adiposity, insulin 
resistance, and T2D with cognitive impairment and dementia (Baker et al., 2011). However, 
there are several important questions to be addressed for investigators studying the relation 
of insulin resistance and AD. For example is not clear if the association between insulin 
resistance and AD is causal. However, one of the links found is that defects in brain insulin 
signaling have been reported in AD and it has been proposed that insulin resistance could 
be an early marker of AD (Baker et al., 2011) (Figure 2). 
 
 
Fig. 2. Insulin deficency can lead to Abeta plaques formation and Tau hyperphos-phorylation 
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Insulin crosses the blood-brain barrier, and might even be produced locally in the brain, 
exerting its effects on cells by binding to a specific cell surface receptor. Insulin receptors are 
expressed throughout the CNS, expecially in the hippocampus and cortex, even if their 
function in the brain is not fully understood. Binding of insulin to its receptor activates the 
intrinsic tyrosine kinase activity of the cytoplasmic domain of the insulin receptor. This 
leads to autophosphorylation of tyrosine residues, which initiates several intracellular 
signaling cascades. In the brain, insulin influences the release and reuptake of 
neurotransmitters, and also appears to improve learning and memory (Zhao et al., 2004). 
The initial components of the insulin receptor signaling cascade in the brain are largely 
similar to those of the periphery. The downstream targets of the cascade are quite different, 
however, probably involving, among others, neuronal glutamate receptors (Zhao et al., 
2004). Neurodegeneration and cognitive impairment in T2D and AD could be caused, in 
part, by damage to insulin receptor signaling (de la Monte & Wands, 2005). In fact, 
decreases in the sensitivity of such receptors are known to affect the expression and 
metabolism of Abeta and tau and impaired insulin receptor activity and hyperinsulinemia 
are observed in patients with AD and in animal models of this disease (Frolic et al., 1998). In 
addition, dysfunction of insulin receptor signaling is associated with impairments in Abeta 
oligomer clearance (Zhao, 2009) and increases the rate of NFT development (Lesort & 
Johnson, 2000). In fact, insulin transiently increases tau phosphorylation in primary cortical 
neurons, and hyperinsulinemia results in tau hyperphosphorylation in rat brains. 
Furthermore, insulin receptor substrate 2 knockout mice demonstrate typical pathological 
signs of T2D and have an increased number of NFTs in hippocampal neurons compared 
with control wild-type mice (Schubert, 2003). Thus, impaired insulin signaling could 
increase tau phosphorylation and cleavage. Insulin receptor signaling leads to the activation 
of two major signaling pathways, the mitogen-activated protein kinase (MAPK) pathway 
and the Akt signaling pathway. MAPK signaling is a required component of cell 
differentiation, cell proliferation and cell death, whereas Akt signaling is involved in the 
regulation of cell growth, cell proliferation, protein synthesis (via the mammalian target of 
rapamycin signaling pathway) and cell survival (through the inhibition of several 
proapoptotic agents). 
Akt signaling induces the inhibition of glycogen synthase kinase-3β (GSK-3β) 
phosphorylates and, hence, inactivates glycogen synthase, a key enzyme in glycogenesis 
(Balaraman et al., 2006). Thus, under normal conditions, insulin signaling via the insulin 
receptor leads to GSK-3β inactivation, whereas insulin resistance leads to GSK-3β 
dephosphorylation and activation (Balaraman et al., 2006). The regulation of GSK-3β in the 
hippocampus and cortex changes in response to changes in glucose and insulin 
concentrations and in T2D an increase in GSK-3β activity might lead to insulin resistance by 
reducing glucose clearance (Lee & Kim, 2007). Increased GSK-3β activation might also lead 
to an elevation in Abeta production (resulting from a GSK-3β-mediated increase in 
presenilin 1 activity) and an increase in tau phosphorylation associated with NFT formation 
(Balaraman et al., 2006; Phiel et al., 2003).  In contrast, inhibition of GSK-3β attenuates APP 
processing and inhibits hyperphosphorylated tau-associated neurodegeneration in cell-
culture and animal models of AD (Phiel et al., 2003). 
Another important link between insulin resistance and the amyloid cascade may be related 
to the insulin degrading enzyme (IDE). This enzyme is a metalloprotease responsible for 
insulin degradation and is also the main enzyme responsible for Abeta degradation (Farris 
et al., 2003). IDE is secreted to the extracellular space by microglial cells in the brain, where 
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it degrades Abeta peptide, thus reducing the rate of aggregation and the plaque formation 
(Qiu et al., 1998). IDE levels have been reported to be decreased in the brains of AD patients 
(Cook et al., 2003). It has also been hypothesized that hyperinsulinemia in people with pre-
diabetes and T2D effectively sequesters IDE, reducing Abeta peptide degradation. This 
would increase levels of Abeta, and promote many of the pathological features associated 
with Alzheimer's disease. Supporting this model, the affinity for the binding of insulin to 
IDE is much greater than that for the Abeta (Qiuet al., 1997). In patients with Alzheimer's 
disease, IDE expression in the hippocampus is substantially reduced, with regards to 
controls, in particular among patients with the APOEvar epsilon4 genotype. This latter 
observation could explain the potential interaction between diabetes and the APOEvar 
epsilon4 genotype in multiplying the risk of dementia (Cook et al., 2003). Curiously, 
although the presence of the APOEvar epsilon4 is associated with an increased incidence of 
Alzheimer's disease, it seems that insulin resistance is only a significant risk factor for AD in 
those patients without APOEvar epsilon4 (Craft et al., 1998). Subjects with AD without the 
APOEvar epsilon4 also had improved memory scores when they had hyperinsulinemia, 
which was not the case for people with at least one APOEvar epsilon4 allele (Craft et al., 
1999). 
However, unexpectedly, recent clinicopathological studies have shown no evidence that the 
pathological hallmarks of AD, including amyloid plaque, were increased in the brains of 
diabetic patients. This suggests that T2D could affect the pathogenesis of AD through 
mechanisms other than modulation of Abeta metabolism even if the underlying 
mechanisms for this association remain largely unknown (Takeda et al., 2011).  
8. FOXO: A common biomarker for AD and T2D 
There is ongoing interest in defining mechanisms that govern insulin resistance and AD. 
The O subfamily of Forkhead/winged helix transcription factors (FOXO) plays important 
roles in regulating key physiological functions, including cell proliferation, cell 
differentiation, and survival together to cell cycle arrest and apoptosis.  (Accili et al., 2004; 
Huang et al., 2007: van der Horst & Tindall, 2007). Thus, FOXO transcription factors are key 
players in cell death/life pathways.  In addition, FOXO works in a complex way to regulate 
insulin signaling and glucose and lipid metabolism (Accili et al., 20004; Barthel et al., 2005). 
An additional layer of complexity exists in the transciptional activity of FOXO that is 
regulated by insulin through the phosphatidyl inositol 3 kinase (PI3K)/Akt signaling 
pathway. Both insulin and insulin-like growth factor-1 (IGF-1), through activation of their 
receptors, induce PI3K/Akt-dependent phosphorylation of FOXO, which facilitates its 
interaction with 14-3-3 protein, leading to nuclear exclusion and eventual ubiquitylation-
dependent proteasomal degradation (Matzusaki et al., 2006). In particular, in presence of 
insulin, activated Akt translocates to the nucleus where directly phosphorylates FOXO at 
distinct sites stimulating interaction with 14-3-3 protein (Greer and Brunet, 2005). This 
chaperone protein promotes the nuclear export and inhibits the nuclear import of FOXO 
proteins, driving the cells towards cell survival (van der Heide et al., 2004). In contrast, 
FOXO proteins, under conditions of oxidative stress, are phosphorylated by other protein 
kinases, including Mst1 and JNK, able to disrupt its interaction with 14-3-3, promoting 
FOXO nuclear translocation and thereby inducing cell death in neurons, thus opposing 
Akt’s action (Sunayama et al., 2005). Thus, it is well established that Akt plays a key role in 
repressing FOXO transcriptional activity. Immediately upstream from FOXO, the activity of 
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Akt itself is governed by several protein kinases and phosphatases. Akt is activated by 
phosphorylation at Thr-308 within its catalytic domain by 3-phosphoinositide-dependent 
protein kinase-1 (PDK1) and by phosphorylation at Ser-473 within a C-terminal 
hydrophobic motif by mammalian target of rapamycin (mTOR) (Stokoe et al., 1997; 
Sarbassov et al., 2005). Some studies show that phospho-Thr-308 and phospho-Ser-273 are 
dephosphorylated by protein phosphatase 1 (PP1), protein phosphatase 2A (PP2A), and 
pleckstrin homology (PH) domain leucine rich repeat protein phosphatase (PHLPP), a 
member of the protein phosphatase 2C family (Gao et al., 2005). Akt regulates a variety of 
key physiological functions, and there is strong evidence suggesting that defective Akt 
signaling contributes to development of insulin resistance (Zdychova & Komers, 2005).  
However, although it is clear that FOXO governs multiple events in the insulin signaling 
cascade, mediating both positive and negative effects, the underlying molecular 
mechanisms are unknown.  Some evidence has been reported that FOXO3 activation is also 
able to increase basal levels of Akt phosphorylation and kinase activity thus it is capable to 
activating its own inhibitor, providing a feedback regulation (Ni et al., 2007) . Moreover, 
FOXO transcription factors are involved in both the insulin action and the cellular response 
to oxidative stress, thereby providing a potential integrative link between AD and insulin 
resistence (Manolopoulos et al., 2010). Both insulin resistence and oxidative stress due to 
Abeta stimulus, may promote the transcriptional activity of FOXO proteins, resulting in 
hyperglycaemia and a further increased production of ROS.  
The consecutive activation of c-Jun N-terminal kinases and inhibition of Wingless (Wnt) 
signalling may result in the formation of Abeta plaques and tau protein phosphorylation. 
Wnt inhibition may also result in a sustained activation of FOXO proteins with induction of 
apoptosis and neuronal loss, thereby completing a vicious circle from oxidative stress, 
insulin resistence and hyperglycaemia back to the formation of ROS and consecutive 
neurodegeneration. Thus, it has been proposed that FOXO proteins may provide a potential 
molecular target for the treatment of both insulin resistence and AD (Manolopoulos et al., 
2010). Recently it has been demostrated that insulin plays a protective role by inhibiting 
mithocondrial dysfunction and apoptosis activation triggered by Abeta oligomers (Di Carlo 
et al., 2010) (Figure 3). 
 
 
Fig. 3. Insulin recovers mitochondrial respiratory activity reduced by rAb42 oligomers. LAN5  
untreated (control), treated with rAb42 oligomers oligomers), and rAb42 oligomers and 
insulin (oligomers+insulin) were incubated with Mito Red and Hoechst 33258. The images 
of each sample were merged. Mitochondrial activity is indicated by red arrows, 
fragmentation of nuclei is indcate by blu arrows. 
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Moreover, unpublished results indicate that insulin counteracts oxidative stress induced by 
amyloid beta by activation of Akt survival pathway. Akt traslocates from the cytoplasm to 
nucleus where phophorylates FOXO3a  that, in turn, moves from the nucleus to the 
cytoplasm inhibiting, in this way the transcription of  the FOXO-dependent genes. Since 
after Abeta-induced oxidative stress are usually activated pro-apoptotic genes, their 
trascriptional inhibition helps the survival program (Picone et al., 2011). Moreover, it has 
been suggested that since insulin signalling in the brain is known to decline with age, the 
outcome of the balance of different molecules, as Akt and FOXO, represents a risk factor for 
AD that is well suited for therapeutic intervention. By restoring the balance of molecules to 
favour neuron survival, new drugs, designed to specifically enhance CNS insulin signalling, 
would provide a new and potentially significant class of AD therapeutics. 
9. Conclusions 
The present chapter highlights the overlap and the many points of intersection existing 
between T2D and AD. Insulin resistence in the CNS results in the dysregulation of multiple 
extracellular and intracellular signaling cascades and molecular mechanisms, which in turn 
could lead to decrease in neuronal and synaptic functions up to neurodegeneration. An 
understanding of how each molecular pathway intersects and affects the others is essential 
for the development of future drug intervention strategies for these pathologies. 
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